Antonio Simone Laganà1, Salvatore Giovanni Vitale2, Vincenzo Muscia3, Paola Rossetti3, Massimo Buscema3, Onofrio Triolo2, Agnese Maria Chiara Rapisarda4, Loretta Giunta5, Vittorio Palmara2, Roberta Granese2, Helena Ban Frangež6, Andrea Romano7. 1. Unit of Gynecology and Obstetrics, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy. antlagana@unime.it. 2. Unit of Gynecology and Obstetrics, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy. 3. Unit of Diabetology and Endocrino-Metabolic Diseases, Hospital for Emergency Cannizzaro, Catania, Italy. 4. Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy. 5. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. 6. Department of Reproduction, University Medical Center Ljubljana, Ljubljana, Slovenia. 7. Department of Gynecology and Obstetrics, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Abstract
PURPOSE: Hysteroscopic surgery is considered the gold standard for the minimal invasive treatment of many endouterine diseases such as endometrial polyps or submucous myomas. Recently, many studies have evaluated the effect of preoperative administration of a number of drugs to reduce endometrial thickness and achieve important intraoperative advantages. The purpose of this systematic review is to summarize the available evidence about the use of Dienogest, an orally administrable progestin, for endometrial preparation before hysteroscopic surgery. METHODS: All studies published on this topic and indexed on PubMed/MEDLINE, Embase or Google scholar databases were retrieved and analysed. RESULTS: We retrieved five studies about this topic. Considered together, the published data analyses allow us to conclude that Dienogest is effective in reducing the thickness of the endometrium, the severity of bleeding and also of operative time, with a lower number of side effects compared with other pharmacological preparations or no treatment. CONCLUSION: Administration of Dienogest may be an effective and safe treatment for endometrial thinning before operative hysteroscopy. However, this conclusion is based on few reports and further studies to prove or disprove it are warranted.
PURPOSE: Hysteroscopic surgery is considered the gold standard for the minimal invasive treatment of many endouterine diseases such as endometrial polyps or submucous myomas. Recently, many studies have evaluated the effect of preoperative administration of a number of drugs to reduce endometrial thickness and achieve important intraoperative advantages. The purpose of this systematic review is to summarize the available evidence about the use of Dienogest, an orally administrable progestin, for endometrial preparation before hysteroscopic surgery. METHODS: All studies published on this topic and indexed on PubMed/MEDLINE, Embase or Google scholar databases were retrieved and analysed. RESULTS: We retrieved five studies about this topic. Considered together, the published data analyses allow us to conclude that Dienogest is effective in reducing the thickness of the endometrium, the severity of bleeding and also of operative time, with a lower number of side effects compared with other pharmacological preparations or no treatment. CONCLUSION: Administration of Dienogest may be an effective and safe treatment for endometrial thinning before operative hysteroscopy. However, this conclusion is based on few reports and further studies to prove or disprove it are warranted.
Authors: Pietro Cignini; Salvatore Giovanni Vitale; Antonio Simone Laganà; Antonio Biondi; Valentina Lucia La Rosa; Giuseppe Cutillo Journal: Updates Surg Date: 2017-01-20
Authors: Salvatore Giovanni Vitale; Salvatore Caruso; Michal Ciebiera; Péter Török; Jan Tesarik; George Angelos Vilos; Aarathi Cholkeri-Singh; Ferdinando Antonio Gulino; Mohan Shashikant Kamath; Antonio Cianci Journal: Arch Gynecol Obstet Date: 2020-03-05 Impact factor: 2.344
Authors: P Giampaolino; N De Rosa; I Morra; A Bertrando; A Di Spiezio Sardo; B Zizolfi; C Ferrara; L Della Corte; G Bifulco Journal: Biomed Res Int Date: 2018-03-05 Impact factor: 3.411